IMCD acquires Trichem to accelerate its growth in the pharmaceutical markets in India Rotterdam, The Netherlands (26 June 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited and Chemistry & Health FZ LLC. Founded in 1998 and headquartered in Mumbai, India, Trichem has built a strong reputation in the healthcare sector, supplying high-quality active pharmaceutical ingredients, pharm...
IMCD to accelerate food & beverage growth in Iberia with strategic acquisition of Ferrer Alimentación Rotterdam, The Netherlands (6 June 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has signed an agreement to acquire 100% of the shares in Ferrer Alimentación, S.A. and Medir Ferrer Y Compañía, S.A. (jointly “Ferrer Alimentación”). Founded in 1955, Ferrer Alimentación is a leading distributor in Iberia of food and beverage ingredients. Ferrer Alimentación is well established and recognised for ...
IMCD to acquire TECOM Ingredients to strengthen its offering in the food & nutrition market in Spain Rotterdam, The Netherlands (16 May 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has signed an agreement to acquire 100% of the shares in TECOM Ingredients S.A. (“TECOM”). Founded in 1996 and headquartered in Molins de Rei, near Barcelona, Spain, TECOM is a recognised distributor of ingredients and additives to the food industry. The company is a trusted partner for customers active in the food...
After surprisingly good numbers 1Q25, we believe there is more upside but 1Q has the easiest comp. Also, trade tariffs might disturb the distribution chain of chemicals. Overall, we modestly adjust our estimates for FY25-27, but we do not change our BUY rating. IMCD is in excellent shape in our view – the company's track record in growth, value enhancement and M&A continues, and its strong asset light model is intact. The share price fall since December has led to 18% lower multiples, suggesting...
A director at IMCD NV bought 840 shares at 118.690EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
In this note we adjust our numbers to reflect the increased uncertainty which results in lower organic growth for FY25 and FY26. While the Gross Profit margin remained robust, OpEx was well above expectations across all regions. Due to these dynamics we lower our forecasted FY25 EBITA by 6% to € 548m. Furthermore, we dive into the divergence with Azelis as this stood out in 1Q25. Our adjustments result in a lower valuation of € 147 per share. Given the upside we maintain our Accumulate recommend...
Shareholders IMCD N.V. adopt all resolutions at AGM Rotterdam, The Netherlands (25 April 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, announces that all resolutions proposed to the shareholders at the Annual General Meeting of Shareholders (AGM) held today were adopted. The resolutions included the adoption of the financial statements for the year 2024 and the proposal of a cash dividend of EUR 2.15 per share. The dividend calendar is as follows: 29 April 2025 Ex-dividend dat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.